Radical efficacy evaluation of comprehensive interventionai therapy for primary hepatocellular carcinoma

( views:, downloads: )
Author:
ZHANG Liang(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
FAN Wei-jun(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
ZHAO Ming(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
LI Chuan-xing(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
TANG Tian(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
Journal Title:
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
Issue:
Volume 15, Issue 04, 2009
DOI:
10.3760/cma.j.issn.1674-1927.2009.04.005
Key Word:
Liver neoplasms;Combined medality therapy;Transeatheter arterial chemoembolization;Radio frequency ablation;Percutaneous ethonal injection

Abstract: Objective To explore the clinical value of interventional invasive therapy in primary hepatocellular carcinoma (PHCC) and it' s radical efficacy. Methods The retrospective analysis was undertaken in 538 patients between January 2003 and January 2008 in our hospital with PHCC. The treatment and the radical efficacy were evaluated. Results Twenty patients(3.7%, 20/538) get progression after the first treatment, 518 patients (518/538) had ever gained effective cure, of whom progression occurred in 416 patients (77.3%, 416/538)at last. The earliest progression occurred 4 months after the first therapy, and the latest occurred 24 months later. One hundred and two (19.0%, 102/538) patients gained evident effective cure, 53 of whom gained radical cure, and they are still alive. The longest follow-up time was 64 months, the shortest was 16 months, and the median survival span estimation in the recent follow-up was 36.5 months. Conclusion Comprehensive interventional therapy is an effective and safe therapy for PHCC, and some patients can gain radical cure.

  • [1]吴孟超,沈峰,吴东.原发性肝癌的外科治疗.中华肝胆外科杂志,2005,11:75-77.
  • [2]Aluarez R,Banares R,Echenagusia A,et al.Prognostic factors survival following transarterial chemoembolization in advanced hepatocellular carcinoma.Gastroenterol Hepatol,2000.23:153-158.
  • [3]Georgiades CS,Hong K,Geschwind JF.Radiofrequency ablation and chemoembolization for hepatocellular carcinoma.Cancer J,2008,14:117-122.
  • [4]Kamel IR,Liapi E,Reyes DK,et al.Unresectable hepatocellular carcinoma:serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.Radiology,2009,250:466-473.
  • [5]Ressi S,Fornari F,Pathios C,et al.Thermal lesions induced by 480 kHz localized current field in guinea pig and pig liver.Tumori,1990,76:54-57.
  • [6]Lau WY,Lai EC.The current role of radiofrequency ablation in the management of hepatocellular carcinoma:a systematic review.Ann Surg,2009,249:20-25.
  • [7]Cho YK,Kim JK,Kim MY,et al.Systematic review of randomised trials for hepatocellular carcinoma treated with pereutaneous ablation therapies.Hepatoiogy,2009,49:453-459.
  • [8]Howard JH,Tzeng CW,Smith JK,et al.Radiofrequency ablation for unresectable tumors of the liver.Am Surg,2008,74:594-600.
  • [9]Tanaka K,Nakamara S,Numata K,et al.The Iong term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis.Cancer,1998,82:78-85.
  • [10]张福君,吴沛宏,赵明,等.肝动脉栓塞化疗后射频消融联合乙醇消融对原发性肝癌的疗效评价.中华肿瘤杂志,2005,27:248-250.
  • [11]熊树华,刘宝琴,胡凯,等.碘化油对肝脏高强度聚焦超声治疗剂量的影响.中华实用外科杂志,2003,2:182.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn